MyoD-Induced Trans-Differentiation: A Paradigm for Dissecting the Molecular Mechanisms of Cell Commitment, Differentiation and Reprogramming

Cecilia Battistelli, Sabrina Garbo and Rossella Maione *

Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
* Correspondence: rossella.maione@uniroma1.it; Tel.: +39-06-4991-8236

Abstract: The discovery of the skeletal muscle-specific transcription factor MyoD represents a milestone in the field of transcriptional regulation during differentiation and cell-fate reprogramming. MyoD was the first tissue-specific factor found capable of converting non-muscle somatic cells into skeletal muscle cells. A unique feature of MyoD, with respect to other lineage-specific factors able to drive trans-differentiation processes, is its ability to dramatically change the cell fate even when expressed alone. The present review will outline the molecular strategies by which MyoD reprograms the transcriptional regulation of the cell of origin during the myogenic conversion, focusing on the activation and coordination of a complex network of co-factors and epigenetic mechanisms. Some molecular roadblocks, found to restrain MyoD-dependent trans-differentiation, and the possible ways for overcoming these barriers, will also be discussed. Indeed, they are of critical importance not only to expand our knowledge of basic muscle biology but also to improve the generation of skeletal muscle cells for translational research.

Keywords: MyoD; myogenic conversion; forced differentiation; chromatin regulation

1. Introduction

Trans-differentiation, also referred to as direct somatic lineage conversion [1,2], is a process in which a differentiated cell type is induced to change identity towards another differentiated state, without passing through a progenitor stage [3]. Trans-differentiation studies have several scopes, ranging from the dissection of the molecular pathways of commitment and differentiation for basic cell biology knowledge, to the generation of large amounts of a desired differentiated cell type (starting from patient derived cells) for genetic disease modeling, drug discovery and therapeutic purposes in regenerative medicine. Decades of research and countless studies involving diverse original cell types and diverse target cell fates have shown that trans-differentiation can be accomplished by means of different approaches [2,4,5]. The most direct, efficient and widely used strategy for inducing a specific cell lineage gene expression pattern consists in the ectopic expression of transcription factors specific to that lineage, using several delivery methods. As an alternative to transgene expression, some studies demonstrated the possibility of activating the regulatory regions of the endogenous factors through CRISPR/Cas9-based transcriptional regulation [6,7]. Trans-differentiation can be also attained through the manipulation of signaling or metabolic pathways, which ultimately affect the transcription factors’ activity and, even more efficiently, through the exposure to small signaling molecules combined with the introduction of lineage-specific factors [8]. More recently, increasing attention is being devoted also to microRNAs and to their regulatory networks as potential drivers of trans-differentiation [9].

A different route in the change of cell identity is the reprogramming of somatic cells into induced pluripotent stem cells (iPSC) that have the potential to differentiate, at least in...
principle, in almost any cell type [10], as reported in many excellent reviews on this topic (see for example [11–15]).

The present review will be focused on the molecular mechanisms underlying the direct route of skeletal muscle conversion of somatic cells driven by the skeletal muscle differentiation factor MyoD. The extensive knowledge learned not only on the molecular mechanisms of myogenesis but also on the general principles underlying commitment, differentiation and dedifferentiation processes will be highlighted.

MyoD holds a special place in the history of cell reprogramming, being the first transcription factor found capable of directly converting differentiated cell types into a different lineage, the skeletal muscle [16]. MyoD was discovered many years ago as a result of a series of elegant experiments initiated with the analysis of myogenic differentiation in heterokaryons [17–19] and with the observation that mouse fibroblast cells treated with the DNA demethylating agent 5-azacytidine were stably converted to chondrogenic, adipogenic and myogenic cells [20–22]. These findings, interpreted with the possible derepression of regulatory loci coding for lineage-specific transcription factors, were followed by the screening of cDNA libraries from 5-azacytidine-derived myoblasts, which led to the cloning of the myogenic determination gene number 1 (MyoD) [23]. It was subsequently found that ectopic MyoD expression could induce skeletal muscle differentiation markers not only in fibroblasts, which are of mesodermal derivation, like myoblasts, but even in some cell types derived from the two other germ layers [24,25].

At that time, the value of the MyoD discovery was to provide not only an additional and direct confirmation of the plasticity of the differentiated state, but also the first evidence that a single transcription factor can set up a complex program of gene expression leading to the acquisition of a differentiated phenotype. On the basis of this insight, a great effort was, and still is, dedicated to the identification of other transcription factors capable of reprogramming the cell fate. In this regard, a number of studies reported the successful induction of neuronal cell types [26,27] and of cardiac myocytes [28,29], starting from more or less distantly related cell types. Other works reported lineage conversions between blood cells [30,31] and between endodermal lineages [32]. Some common features shared by trans-differentiation factors emerged from these studies. For example, many of them are lineage-specific transcription factors required for critical developmental phases. More importantly, the majority of them are “pioneer” factors; indeed, they are capable of accessing closed chromatin, a crucial property that accounts for their ability to overcome the restrictions present in the differentiated cell to be reprogrammed [33]. Furthermore, they act as master regulators that induce cascades of key downstream factors cooperating in lineage specification and differentiation [34,35]. Remarkably, however, while most of the reprogramming processes require the combined expression of several transcription factors, MyoD is sufficient, even when expressed alone, to induce the myogenic conversion of somatic cells. Why MyoD is more powerful with respect to other reprogramming factors in inducing trans-differentiation is still an open question. Some possible explanations are to be sought in the MyoD’s capability of engaging a complex network of co-factors, to activate positive feedbacks and to exploit diverse epigenetic strategies that cooperate for dramatically changing the transcriptional program of the cells to be converted.

2. Transcriptional Activation by MyoD

MyoD is a muscle-specific member of the basic helix–loop–helix (bHLH) class of proteins, a large family of transcription factors recognizing short DNA sequences (CANNTG), termed E-box motifs, in the regulatory regions of target genes [36]. The MyoD protein (UniProt codes P10085 and P15172 for mouse and human proteins, respectively) contains a basic domain, involved in DNA binding, which is a HLH domain involved in dimerization with other HLH proteins, and two less conserved N-terminal and C-terminal domains, involved in transcriptional activation [37,38]. MyoD binding to E-boxes and the subsequent transactivation require heterodimerization with ubiquitous bHLH E-proteins, such as E12 and E47 [39]. The specificity of DNA binding and target activation by MyoD is
determined by the cooperation of several mechanisms, such as the preference for internal and flanking sequences of E-boxes, the heterodimerization partners, the cooperation with other transcriptional regulators and the pre-existing chromatin accessibility [40–43]. Some transcription factors, such as MEF2 family members [44,45], Sp1 [46,47], Pbx [48] and Six proteins [49], cooperate with MyoD by directly binding to adjacent sites. A widespread role of these factors in MyoD co-regulation was further supported by studies based on the genome search for sequence motifs associated with MyoD binding regions [50,51]. A number of other factors, identified as MyoD partners by proteomic approaches [52,53] could be indirectly recruited by the myogenic factor to its target sites and modulate its activity. MyoD also interacts with the basal transcription machinery [54,55] and with the transcription elongation factor b, P-TEFb [56,57]. However, as it will be explained in detail below, a crucial role in MyoD co-activation is played by the physical and functional interaction of the myogenic factor with the epigenetic machinery.

MyoD binding and activity can be also negatively regulated. The Id proteins, which contain the HLH but not the basic domain, antagonize MyoD binding by sequestering E proteins, thus preventing the formation of active heterodimers [36,58]. Other MyoD inhibitors, such as MyoR/musculin [59,60], Twist proteins [61,62] and Mist1 [63], are bHLH proteins. These factors affect MyoD function through a combination of mechanisms, including the sequestration of E proteins, the competition with MyoD for DNA binding and the heterodimerization with MyoD into non-functional complexes. Other examples are represented by the zinc finger proteins Snail [64] and ZEB1 [65], which inhibit MyoD function by binding to the same E-boxes, where they recruit co-repressors that reduce chromatin accessibility.

Importantly, MyoD-dependent transcription is linked with extracellular cues through several signaling cascades. The best characterized is the p38 MAP kinase pathway, which promotes MyoD activity by targeting co-factors such as MEF2 and E proteins, as well as MyoD-interacting chromatin complexes [66–68]. On the other hand, the activation of the Notch pathway inhibits MyoD function through the Notch effector Hes1/Hey1, a bHLH transcriptional repressor that competes with MyoD for E-box binding [69]. Several mitogenic signals also inhibit MyoD function through multiple mechanisms, among which are the up-regulation of Id proteins and the activation of cyclin/cdk complexes that directly target MyoD [70]. This is why efficient in vitro differentiation of myogenic cells requires the withdrawal of serum from the culture medium. Interestingly, while the presence of mitogens during myogenic conversion prevents terminal differentiation, it does not seem to prevent the commitment step to the myoblast precursor; as revealed by a genome-wide transcriptome analysis, in this condition, the up-regulation of myoblast-specific and the down-regulation of cell-of-origin networks are observed [71]. This finding should be addressed more in depth, as it would mean the possibility of separately studying the commitment and differentiation steps.

MyoD-induced trans-differentiation involves the activation of a complex program of gene expression, which starts with the activation of direct targets such as the bHLH muscle-specific transcription factor myogenin and the co-activator MEF2 [72]. MyoD also induces its own transcription [73] and the expression of other transcription factors [72]. These factors, in turn, activate downstream muscle-specific genes, acting through amplifying cascades or through feed-forward mechanisms involving the cooperation with MyoD itself [72,74,75]. Trans-differentiation by MyoD is associated not only with the acquisition of the muscle phenotype by the cell undergoing conversion, but also with the loss of the original phenotype [24,25]. Indeed, global analyses of gene expression during fibroblast-to-muscle conversion revealed that many, though not all, fibroblast-related genes are down-regulated [71,76]. Although MyoD is a transcriptional activator, it can repress some genes negatively regulating myogenesis through the induction of microRNAs (e.g., MyoD induces the expression of miR-206, which targets Fstl1 and Utrn, suppressed during skeletal muscle differentiation) [77]. Moreover, MyoD is capable of keeping some muscle-specific genes in proliferating myoblasts repressed until the occurrence of a differentiation signal, through
the recruitment of chromatin-compacting enzymes [78] (see also below). However, the molecular mechanisms by which MyoD can turn off the fibroblast differentiation program and, even harder to explain, any original differentiation program are still puzzling.

A schematic representation of the best characterized co-factors and signaling pathways that promote or inhibit the transcriptional activation by MyoD is illustrated in Figure 1.

Figure 1. Regulation of MyoD transcriptional activity. The drawings outline some of the main co-factors (A) and signaling pathways (B) that promote or inhibit the transcriptional activation by MyoD.

The discovery of MyoD was followed by the identification of three other bHLH muscle regulatory factors (MRFs) structurally and functionally related to MyoD and exclusively expressed in skeletal muscle: myogenin [79], Myf5 [80], and MRF4 [81]. In vivo studies addressing the spatio-temporal expression pattern of MRFs and the effects of their genetic ablation on muscle development, differentiation and regeneration, highlighted both over-
lapping and specific roles for these factors. The general picture emerging was that MyoD and Myf5 are involved in the commitment of muscle precursors to the myogenic lineage, myogenin in terminal differentiation and MRF4 in both phases of myogenesis \[82–84\]. Although all of them were shown to induce skeletal muscle markers when ectopically expressed in fibroblast cells, none of them were able to drive myogenic conversion as efficiently as MyoD \[85,86\]. Comparative analyses for genome-wide binding, induction of chromatin modifications and regulation of gene expression have been focused on MyoD, Myf5 and myogenin \[87,88\], but not yet on MRF4. These studies suggested that Myf5 is more active as a chromatin modifier than as a transcriptional activator, myogenin is principally a transcriptional activator, while MyoD possesses both a potent transactivation domain and the ability to initiate chromatin modifications.

3. Chromatin Regulation by MyoD

The chromatin status, extremely important for transcriptional control during the changes of cell identity, is determined by several regulatory layers, such as the density and positioning of nucleosomes, the different histone post-translational modifications and the folding of the chromatin fiber into higher-order structures of different length scales. The dynamics of these regulatory layers, driven by the interplay between cis-regulatory elements, transcription factors, chromatin-modifying enzymes and long noncoding RNAs, are strictly interdependent on each other \[89–91\].

One of the key properties by which MyoD can initiate cell reprogramming is believed to be its ability to contact E-boxes within closed chromatin, the typical feature of the so-called “pioneer” transcription factors \[33\]. Actually, MyoD was supposed to have a weak pioneer activity due to the structural features of its bHLH domain \[92\]. In fact, it has been found that, during differentiation, the binding of MyoD to the myogenin promoter is preceded by the binding of the homeodomain protein Pbx \[48\]. Pbx would allow the recruitment of the myogenic factor to a non-canonical E-Box by physically interacting with MyoD; then, chromatin modifications, increased accessibility of the adjacent canonical E-boxes, stable MyoD binding and further chromatin remodeling at the regulatory region allow the induction of myogenin expression \[48,93,94\]. However, Pbx is required for several but not all MyoD-regulated genes \[42,95\]. Moreover, a genome-wide analysis of chromatin accessibility in embryonic stem cells through ATAC-seq and MNase-seq showed that MyoD can bind to sites previously embedded in closed chromatin and subsequently induce chromatin modifications \[96\].

Regardless of the assistance of other factors in accessing chromatin, MyoD is capable of dramatically reorganizing the chromatin landscape of trans-differentiating cells by engaging and coordinating multiple epigenetic mechanisms (detailed below and schematized in Table 1 and Figure 2).

**Table 1.** Key factors exploited by MyoD for reprogramming the chromatin state.

| Class                      | Recruited or Targeted Factor | MyoD-Induced Effect                                           | References |
|----------------------------|------------------------------|--------------------------------------------------------------|------------|
| Nucleosome remodeling factors | SWI/SNF complex              | Relaxation of nucleosome positioning at MyoD targets         | \[93,97,98\] |
|                            | CHD2                         | Incorporation of the histone variant H3.3 and marking of muscle promoters for activation | \[99\]     |
Table 1. Cont.

| Class                        | Recruited or Targeted Factor | MyoD-Induced Effect                                                                 | References |
|------------------------------|------------------------------|-----------------------------------------------------------------------------------|------------|
| Histone acetylases and deacetylases | p300/CBP                     | Histone acetylation and transcriptional activation                                 | [72,100,101] |
|                              | pCAF                         | MyoD acetylation and transcriptional activation                                    | [102,103]  |
|                              | HDAC I                       | Histone deacetylation and inhibition of premature activation of MyoD targets       | [78]       |
| Histone methylases and demethylases | Set7/9                       | Accumulation of H3K4me1 and assembly of active muscle enhancers                    | [50,104]  |
|                              | Prmt5                        | H3R8 dimethylation and increased recruitment of the SWI/SNF complex               | [105]      |
|                              | LSD1                         | Demethylation of H3K9me2 and derepression of MyoD targets                          | [106]      |
|                              | Utx                          | Demethylation of H3K27me3 and derepression of MyoD targets                          | [107]      |
| Long noncoding RNAs          | SRA                          | Cooperation with MyoD-induced gene expression                                      | [108,109] |
|                              | Lnc-RAM                      | Support to the assembly of the MyoD-SWI/SNF complex on the regulatory regions of muscle genes | [110] |
|                              | LncMyoD                      | Increase of chromatin accessibility at MyoD binding sites                           | [111]      |
| Architectural proteins mediating chromatin folding | Kcnq1ot1                     | Displacement of EZH2 and release of gene repression at the p57kip2 locus.           | [112]      |
|                              | CTCF                         | Regulation of long-distance chromatin contacts mediated by CTCF                     | [71,113–115] |
Figure 2. Chromatin regulation by MyoD. The drawings outline the best characterized chromatin modifying complexes (A) and long noncoding RNAs (B) exploited by MyoD for chromatin reprogramming.

3.1. Interaction with Nucleosome Remodeling Complexes

The stability and position of nucleosomes can be altered by chromatin remodeling enzymes that, by assembling, disassembling or sliding nucleosomes, can cover or uncover the binding sites for transcription factors [116]. Early evidence that MyoD acts by modifying chromatin accessibility for promoting transcription came from trans-differentiation experiments showing the relaxation of nucleosome positioning at the promoters of MyoD targets [86]. It was subsequently discovered that a key role in this process is played by the ATP-dependent chromatin-remodeling complex SWI/SNF, which is bound and recruited by MyoD on muscle gene promoters [93,97]. SWI/SNF complexes contain either the Brg1 or
the Brm1 ATPase subunit and a variable number of different BAF (Brg1/Brm-associated factors) structural subunits. SWI/SNF complexes are typically involved in sliding and ejecting nucleosomes, thus exposing binding sites for transcriptional activators or repressors. The molecular mechanism by which MyoD directs the SWI/SNF complex to its targets involves the preassembly of a complex containing MyoD and the muscle-specific BAF60c subunit on gene promoters before differentiation, followed by the recruitment of a Brg1-containing SWI/SNF complex upon differentiation stimuli causing BAF60c phosphorylation by p38 kinase [98].

An additional mechanism of MyoD-induced chromatin remodeling involves the direct interaction of the myogenic factor with the CHD2, a member of the CHD subfamily of chromatin remodelers involved in nucleosome editing [99]. By recruiting CHD2 prior to differentiation, MyoD induces the incorporation of the histone variant H3.3 genome wide at myogenic gene promoters, marking them for activation [99].

As also highlighted below, the recruitment of chromatin remodeling complexes is further reinforced by the MyoD-induced chromatin modifications, providing one of the numerous examples of the positive feedbacks activated by the myogenic factor.

3.2. Interaction with Histone-Modifying Enzymes

A wide range of histone modifications including acetylation, methylation, phosphorylation, and ADP-ribosylation affect the degree of local chromatin condensation [89]. Increased knowledge about the epigenetic enzymes involved in the deposition of these modifications and improved methods for mapping their genome-wide distribution partially clarified their relationship with the chromatin structure at promoters and enhancers and with the transcriptional dynamics. Most information concerns the acetylation and methylation of specific residues of H3 and H4 histone tails. For example, acetylation of lysine 9 in histone H3 (H3K9Ac), acetylation of lysine 20 in histone H4 (H4K20Ac), acetylation of lysine 27 in histone H3 (H3K27Ac), mono- or dimethylation of lysine 4 in histone H3 (H3K4me1/2) and tri-methylation of lysine 4 in histone H3 (H3K4me3) are generally associated with chromatin relaxation; in contrast, tri-methylation of lysine 9 in histone H3 (H3K9me3), tri-methylation of lysine 27 in histone H3 (H3K27me3) and tri-methylation of lysine 20 in histone H4 (H4K20me3) are associated with chromatin compaction.

One of the first evidences that MyoD cooperates with histone-modifying enzymes was the interaction of the myogenic factor with the histone acetyltransferase (HAT) p300/CREB [100,101] and the increase of histone acetylation at some MyoD targets in concomitance with MyoD binding and gene activation [72]. Histone hyperacetylation, in turn, reinforces the chromatin accessibility of MyoD targets by promoting the recruitment of the chromatin remodeling SWI/SNF complex [93]. MyoD also associates with the HAT pCAF, but this interaction is mainly involved in its acetylation, a post-translational modification required for MyoD function [102,103,117]. Interestingly, MyoD was found to recruit class I histone deacetylases (HDAC I) to the myogenin promoter and to repress its activation in proliferating, undifferentiated myoblasts [78]. This mechanism would serve for preventing premature differentiation until the replacement of HDACs with HATs. The possible role of HDACs in MyoD-dependent commitment during trans-differentiation, however, is not known. Large scale approaches demonstrated that MyoD binds genome-wide to promoters, enhancers and thousands of additional intergenic sites in undifferentiated myoblasts, differentiated myotubes, as well as in trans-differentiated fibroblasts, and that its binding is associated with the hyperacetylation of histones H3 and H4 [51]. However, the observation that MyoD binding and histone modifications did not necessarily correlate with transcriptional activation suggested a more complex role for MyoD in the reorganization of chromatin architecture (see below).

Another chromatin-modifying enzyme that interacts with MyoD is the histone methyltransferase Set7/9 [104], which promotes the accumulation of H3K4me1, a typical chromatin signature of enhancer regions [118]. Set7/9 is recruited by MyoD on muscle regulatory regions and is required for efficient trans-differentiation of fibroblasts to my-
oblasts [104]. In this regard, the integration of MyoD-binding profile data with the genome-wide distribution of specific chromatin signatures, such as H3K4me1 and H3K27Ac, highlighted the critical role of MyoD in the assembly of active enhancers for the activation of muscle-specific genes [50].

A further histone-modifying enzyme used by MyoD for inducing permissive chromatin at its targets is Prmt5, a protein arginine methyltransferase [105]. Through direct interaction with MyoD, Prmt5 binds to the myogenin promoter, in which it introduces the dimethylation of histone H3 arginine 8 (H3R8). This modification promotes the recruitment of the Brg1 subunit of the SWI/SNF chromatin-remodeling complex and is required for chromatin remodeling and transcriptional activation [105]. Whether the interaction between MyoD and Prmt5 is involved in the wider effects of MyoD binding to the genome has not been investigated yet.

Along with the deposition of activating histone modifications, the induction of MyoD targets also involves the removal repressive chromatin marks such as the methylation of H3K9 and the methylation of H3K27. This is in part due to the decreased expression and/or to signal-dependent post-translational modifications of the enzymes responsible for these modifications. Down-regulation of repressing chromatin enzymes has been reported for: Suv39H1, which catalyzes H3K9me3 [119]; G9a, which catalyzes H3K9 mono and dimethylation; as well as MyoD methylation [120] and EZH2, the catalytic subunit of the polycomb repressive complex 2 (PRC2), which catalyzes H3K27me3 [121,122]. In addition, the removal of repressive methylation from MyoD targets also involves the ability of the myogenic factor to recruit histone demethylases such as LSD1 [106], which targets H3K9me2, and UTX [107], a H3K27me3-specific demethylase. Interestingly, it has been reported that treatment with 2-hydroxyglutarate, which prevents H3K9 demethylation at MyoD targets, inhibits MyoD-mediated trans-differentiation of mouse fibroblasts but not the differentiation of already committed C2C12 myoblasts. Although the putative MyoD-interacting demethylase whose inhibition causes this effect is not known, this finding suggests its specific involvement in the commitment step of the differentiation process [123].

### 3.3. Interaction with Long Noncoding RNAs

A large number of long noncoding RNAs, both ubiquitous and muscle-specific, have been involved in either promoting or restricting skeletal muscle differentiation. These long noncoding RNAs are localized in the nucleus and/or in the cytoplasm and affect myogenesis through diverse mechanisms resulting in chromatin modifications, transcriptional modulation or post-transcriptional regulation [124–126]. Some of the long noncoding RNAs demonstrated as important in myogenesis have been shown to be direct MyoD partners for achieving the transactivation of its targets.

The first long noncoding RNA found to be involved in muscle differentiation was steroid receptor RNA activator (SRA), which physically interacts with MyoD and with the associated RNA helicases p68/p72 at muscle promoters [108]. Depletion of SRA impairs MyoD-induced gene expression and myogenic conversion, indicating a critical role of the observed interaction for MyoD activity [108,109]. The molecular mechanism underlying the cooperation between SRA and MyoD has not been defined. However, it is worth mentioning that SRA can interact with trithorax group (TrxG) or polycomb repressive complex 2 (PRC2) complexes [127] and, interestingly, also with the cohesin complex, regulating CTCF-mediated insulation and chromatin contacts [128].

Linc-RNA activator of myogenesis (Linc-RAM) is a muscle-specific long noncoding RNA associated with chromatin and is required for the activation of a wide range of MyoD targets [110]. The molecular mechanism of this cooperation involves the physical interaction of MyoD with Linc-RAM, which promotes the assembly of the MyoD-SWI/SNF complex on the regulatory regions of muscle genes [110].

Another long noncoding RNA, LncMyoD, is directly activated by the myogenic factor and promotes muscle differentiation through at least two distinct mechanisms [111,129].
One involves the inhibition of the IMP2-mediated translation of proliferation genes, allowing growth arrest that facilitates differentiation [129]. The other one involves the physical interaction of LncMyoD with MyoD across the genome and the increase of chromatin accessibility at the co-occupied sites [111]. Very interestingly, LncMyoD is required for the differentiation of muscle precursors and for the myogenic conversion of fibroblast cells, but not for the differentiation of already committed myoblasts, suggesting its role in the first step of MyoD-mediated trans-differentiation [111].

Further evidence that MyoD makes use of long noncoding RNAs for regulating gene expression is provided by the physical and functional interaction of the myogenic factor with the macro LncRNA Kcnq1ot1 in inducing the expression of the cdk inhibitor p57kip2 [112]. In this case, MyoD exploits the chromatin interaction with Kcnq1ot1 for displacing EZH2 and releasing gene repression.

Some other long noncoding RNAs are involved the activation of MyoD targets, but their direct interaction with MyoD has not been proved. For example, the long noncoding RNA MUNC (also called DRR RNA), a trans-acting enhancer-derived RNA transcribed from the distal regulatory region (DRR) enhancer of MYOD, cooperates with the myogenic factor by promoting MyoD binding and transactivation of some targets [130–132]. The long noncoding RNA Irm is also up-regulated during myogenesis and positively regulates the differentiation process. This long noncoding RNA enhances the expression of MyoD/MEF2 targets by interacting with chromatin at these loci and facilitating the assembly of MyoD/MEF2D complexes. However, Irm does not seem to interact with MyoD, but only with MEF2D [133].

With the advent of increasingly advanced methods for the computational analysis of long noncoding RNA-protein interactions and their genome-wide binding profiles, it will certainly turn out that the use of long noncoding RNAs by MyoD is a more common strategy than we thought.

3.4. Three-Dimensional Genome Reorganization

It has long been recognized that the spatial organization of the chromatin plays an important role in coordinating gene expression during developmental processes [134,135] and that it is regulated by a bidirectional interplay with transcription factors and chromatin modifications [136,137]. The three-dimensional (3D) organization of the genome results from hierarchical levels of chromatin folding [138,139]. The first level involves the formation of chromatin loops, whose sizes vary from kilobases to megabases, and which are involved in several functions including promoter-enhancer interactions. A higher order level involves the folding into topologically associated domains (TADs), which are characterized by the presence of boundaries that constrain the spreading of repressive chromatin and behave as co-regulatory units that limit the genomic interactions within the domain. Both loops and TADs can be stabilized by CCCTC-binding factor (CTCF) in cooperation with the cohesin complex [139]. At a further level, multiple TADs can then associate with each other to form the so-called A and B compartments, euchromatic and heterochromatic, respectively.

The study of MyoD-dependent commitment and differentiation has now provided important insights into the molecular mechanisms underlying the bidirectional interplay between transcription factors and chromatin folding. Early evidence that MyoD can regulate gene expression by altering the spatial organization of chromatin was provided by the regulation of individual MyoD targets. For example, it was reported that MyoD induces the expression of the cdk inhibitor p57kip2 by disrupting a CTCF-mediated chromatin contact of p57 promoter with a repressive regulatory element located about 150 kilobases far from the gene [140]. The molecular mechanism involves the physical and functional interaction of MyoD with CTCF, which results in the displacement of cohesin complex subunits [113]. Moreover, MyoD was shown to drive the formation of repressive inter-chromosomal interactions between the regulatory regions of some muscle genes expressed at late times of myogenesis [114]. These interactions, which are induced by MyoD during...
the commitment to the myogenic lineage, keep late myogenic genes inactive until the appropriate time of differentiation, suggesting a mechanism for the temporal regulation of gene expression during the differentiation process [114].

The development of increasingly sensitive high-throughput chromatin conformation capture (Hi-C) techniques and of very high-resolution imaging methods allowed to reveal that MyoD-dependent differentiation is associated with a global reorganization of the genome architecture [71,115,141]. These studies indicated that MyoD is required for the establishment of genome-wide chromatin contacts between regulatory elements by binding to promoters, enhancers and insulators during the commitment step of fibroblast transdifferentiation [71], as well as in differentiating myoblasts [115]. It is worth mentioning that MyoD binding resulted in transcriptional repression and altered long-range interactions between the regulatory elements of TGF-β1, a fibroblast-related gene [71]. This suggests that the reorganization of the three-dimensional genome architecture may be important in the strategy by which MyoD represses the gene expression program of the cell of origin during reprogramming.

The molecular mechanisms by which transcription factors drive chromatin topology are just beginning to be clarified [136,137] and include, among others, the contribution of the ongoing transcription and/or of the local chromatin structure. However, MyoD-dependent chromatin looping precedes the activation of gene expression and is not altered by the inhibition of transcription [71] nor by the modulation of MyoD-induced H3K27ac levels [115]. The integration of the Hi-C maps with the ChIPseq data for MyoD and CTCF led to the suggestion that MyoD alters the chromatin contacts by functionally interacting with CTCF at loop anchor regions [71,115]. Interestingly, MyoD was also found to function in vitro as an anchor protein, by itself, and suggested to mediate muscle-specific chromatin loops even independently of CTCF [115], but this property has not been further explored.

4. Limits to MyoD-Dependent Trans-Differentiation

Since its discovery, it was realized that MyoD, despite its reprogramming potency, was unable to induce the myogenic conversion of some cell types such as embryonal carcinoma cells, HeLa cells and some hepatocyte-derived cell lines [24,142]. Many efforts have also been made for converting embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells) through exogenous MyoD expression [143,144]. These approaches, aimed at possible applications of patient-derived cells in regenerative medicine, revealed the existence of several constraints to the MyoD-mediated conversion of mouse ES cells [145], human ES cells [146] and human iPS cells [147,148]. The observed limitations, which are the object of extensive investigation, reflect the existence of epigenetic barriers, the lack of trans-acting co-factors (or the presence of trans-acting repressors) and the occurrence of abnormal signaling. For example, the unresponsiveness of HeLa cells to MyoD-mediated conversion was ascribed to the deficiency of Baf60c and of p38 kinase activity [98]. Importantly, the manipulation of this and other epigenetic pathways significantly improved the scarce efficiency of myogenic conversion of human ES cells and iPS cells. In this regard, it was reported that the introduction of exogenous Baf60c allows MyoD to promote chromatin remodeling at myogenic targets and to induce muscle gene expression in embryonic stem cells [146]. Moreover, the exogenous expression of the histone demethylase JMJD3 (KDM6B), which removes di- and tri-methylation from H3K27, combined with that of MyoD, triggers the myogenic differentiation of human-induced pluripotent stem cells, although H3K27 demethylation seems to indirectly affect the activation of muscle-specific genes [147].

It is worth considering that trans-differentiation is not complete even when MyoD is ectopically expressed in fibroblasts, the cell type most amenable to myogenic conversion [76,149].

Epigenetic constraints were described for specific MyoD targets, such as cdkn1c, which is not induced in some fibroblast cell types, while it is in others [150]. The analysis of this model system revealed that an interplay between pre-existing DNA methylation and H3
K9 dimethylation prevents MyoD binding and the consequent chromatin reorganization required for gene activation [151,152].

Another mechanism limiting MyoD function involves poly(ADP-ribose) polymerase 1 (PARP1). PARP1 was reported to keep some paradigmatic MyoD target genes under control during the differentiation process by interfering, independently of the enzyme activity, with MyoD binding and with the accumulation of the activating histone modification H3K4me3 [153]. This kind of interference was observed in differentiating myoblasts, but it is conceivable that PARP1-dependent chromatin features may play a more general role in restricting MyoD function during trans-differentiation processes.

Incomplete trans-differentiation of fibroblast cells was explored at a genome-wide scale through an integrated analysis of gene expression, MyoD binding and chromatin accessibility in MyoD-converted fibroblasts compared to myoblasts [76]. This work revealed that the failure to up-regulate a number of muscle-specific and to down-regulate a number of fibroblast-specific genes was associated with deficiencies in chromatin remodeling. However, the exact relationship between pre-existing chromatin features, MyoD binding and chromatin accessibility was not completely characterized in this study. The recent employment of single-cell transcriptome analysis associated with pseudo-temporal ordering of cells not only confirmed the incomplete reprogramming of human fibroblasts but also allowed the reconstruction of differentiation trajectories during MyoD-mediated conversion [149]. The authors developed a computational method for comparing the pseudo-temporal trajectories of MyoD-converted fibroblasts with those of normal human myoblasts and revealed some of the barriers that divert fibroblast cells from the muscle fate to alternative paths. This approach revealed that MyoD fibroblasts fail in the up-regulation of an IGF1-mediated autocrine signaling, known to support MyoD function through multiple mechanisms, and over-secrete BMP proteins, known to impair MyoD activity by autocrinally inducing ID [149].

Very interestingly, the expression of ectopic MyoD in combination with a cocktail of three small molecules (the cyclic AMP agonist forskolin, the TGF-β inhibitor RepSox and the GSK3-β inhibitor CHIR99021) was shown to reprogram mouse fibroblast cells into induced myogenic progenitor cells (iMPCs), highly similar to satellite cells but more easily expandable and capable of spontaneously differentiating into contracting myotubes [154]. A detailed analysis of the transcriptomic and epigenomic features of the direct conversion to muscle by MyoD alone, compared with the indirect conversion through iMPCs by MyoD plus small molecules, revealed that the two cell fates are reached through distinct molecular trajectories and that the transition through iMPCs leads to a more stable and complete differentiation with respect to the direct route [155,156]. There is no doubt that these studies highlighted a novel approach for producing reliable muscle stem cells for several types of translational applications. However, the molecular mechanism by which MyoD, when combined with small molecules, causes dedifferentiation is not yet clear. In particular, the transcriptional and epigenetic co-factors used by MyoD for the activation of stem cell markers, as well as for the repression of fibroblast cell markers, deserve further investigations.

5. Concluding Remarks

As highlighted throughout the review, one of the most significant outcomes of dissecting the strategies by which MyoD alone succeeds in reprogramming the cell identity was the disclosure of a number of molecular mechanisms underlying the plasticity of the differentiated state and the transcriptional regulation of differentiation processes. These studies led to the identification and characterization of networks involving transcriptional regulators, chromatin interactions, long noncoding RNAs and signaling pathways, in some cases specific to the muscle system but in other cases common to other lineages.

As introduced above, one of the scopes of forcing differentiation towards a specific lineage is the production of functional differentiated cells for therapeutic applications and disease modeling. After an initial excitement regarding the possibility of using ex vivo
MyoD transfer in regenerative medicine, it became clear that the direct lineage conversion does not exactly recapitulate the program of muscle development, especially as regards the down-regulation of the resident gene expression program and the physiological maturation of myofibers. Furthermore, importantly, cells expressing exogenous MyoD tend to be directly driven to terminal differentiation, thus losing the regeneration potential and the property to be expanded. In this regard, intensive research is currently focused on developing protocols, based on the expression of myogenic regulators combined with epigenetic modulators and signaling molecules, for generating muscle progenitors and for improving their differentiation and regeneration potential [143,144]. Further efforts are being addressed toward skeletal-muscle tissue engineering through emerging biotechnologies including self-organized 3D skeletal muscle organoids and scaffold-based platforms mimicking muscle architecture [157].

Nevertheless, it is worth pointing out that exogenous MyoD expression in both pluripotent and somatic cells provides several advantages and opportunities. Exogenous, regulated MyoD expression allows the generation of a large amount of terminally differentiated cells in a simple, fast and inexpensive manner. In this regard, MyoD-induced differentiation of patient-derived iPS cells proved to be useful for recapitulating some of the phenotypes of Duchenne muscular dystrophy and other muscle disorders [148,157]. A deeper exploration of MyoD-induced dedifferentiation of easily accessible somatic cells toward the myoblast precursor stage followed by faithful differentiation [154,156] also appears promising, if this approach could be applicable to human cells.

In conclusion, further insights on the molecular roadblocks to MyoD-induced transdifferentiation and on the networks that facilitate the efficiency of reprogramming and of terminal differentiation are needed, not only to expand our knowledge of basic muscle biology but also to improve the current approaches for disease modeling, drug discovery and new therapeutic approaches.

**Author Contributions:** Conceptualization, R.M.; original draft preparation, R.M.; writing, C.B. and R.M.; review and editing, C.B., S.G. and R.M.; funding acquisition, C.B. and R.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Sapienza University of Rome: RM11715C642DFF3B and RP1181643693916D (to R.M.) SEED PNR 2021 (to C.B.)

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Vierbuchen, T.; Wernig, M. Direct lineage conversions: Unnatural but useful? Nat. Biotechnol. 2011, 29, 892–907. [CrossRef][PubMed]
2. Wang, H.; Yang, Y.; Liu, J.; Qian, L. Direct cell reprogramming: Approaches, mechanisms and progress. Nat. Rev. Mol. Cell Biol. 2021, 22, 410–424. [CrossRef][PubMed]
3. Mills, J.C.; Stanger, B.Z.; Sander, M. Nomenclature for cellular plasticity: Are the terms as plastic as the cells themselves? EMBO J. 2019, 38, e103148. [CrossRef][PubMed]
4. Aydin, B.; Mazzoni, E.O. Cell Reprogramming: The Many Roads to Success. Annu. Rev. Cell Dev. Biol. 2019, 35, 433–452. [CrossRef][PubMed]
5. Shelby, H.; Shelby, T.; Wernig, M. Somatic Lineage Reprogramming. Cold Spring Harb. Perspect. Biol. 2022, 14, a040808. [CrossRef][PubMed]
6. Black, J.B.; Adler, A.F.; Wang, H.G.; D’Ippolito, A.M.; Hutchinson, H.A.; Reddy, T.E.; Pitt, G.S.; Leong, K.W.; Gersbach, C.A. Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell Stem Cell 2016, 19, 406–414. [CrossRef]
7. Chakraborty, S.; Ji, H.; Kabadi, A.M.; Gersbach, C.A.; Christoforou, N.; Leong, K.W. A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Rep. 2014, 3, 940–947. [CrossRef]
8. Xie, X.; Fu, Y.; Liu, J. Chemical reprogramming and transdifferentiation. Curr. Opin. Genet. Dev. 2017, 46, 104–113. [CrossRef]
9. Adlakha, Y.K.; Seth, P. The expanding horizon of MicroRNAs in cellular reprogramming. *Prog. Neurobiol.* **2017**, *148*, 21–39. [CrossRef]

10. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **2006**, *126*, 663–676. [CrossRef]

11. Buganim, Y.; Faddah, D.A.; Jaenisch, R. Mechanisms and models of somatic cell reprogramming. *Nat. Rev. Genet.* **2013**, *14*, 427–439. [CrossRef]

12. Rowe, R.G.; Daley, G.Q. Induced pluripotent stem cells in disease modelling and drug discovery. *Nat. Rev. Genet.* **2019**, *20*, 377–388. [CrossRef] [PubMed]

13. Smith, Z.D.; Sindhu, C.; Meissner, A. Molecular features of cellular reprogramming and development. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 139–154. [CrossRef] [PubMed]

14. Srivastava, D.; DeWitt, N. In Vivo Cellular Reprogramming: The Next Generation. *Cell* **2016**, *166*, 1386–1396. [CrossRef] [PubMed]

15. Takahashi, K.; Yamanaka, S. A decade of transcription factor-mediated reprogramming to pluripotency. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 183–193. [CrossRef]

16. Lassar, A.B. Finding MyoD and lessons learned along the way. *Semin. Cell Dev. Biol.* **2017**, *72*, 3–9. [CrossRef]

17. Blau, H.M.; Chiu, C.P.; Webster, C. Cytoplasmic activation of human nuclear genes in stable heterocaryons. *Cell* **1983**, *32*, 1171–1180. [CrossRef]

18. Blau, H.M.; Pavlath, G.K.; Hardeman, E.C.; Chiu, C.P.; Silberstein, L.; Webster, S.G.; Miller, S.C.; Webster, C. Plasticity of the differentiated state. *Science* **1985**, *230*, 758–766. [CrossRef]

19. Wright, W.E. Induction of muscle genes in neural cells. *J. Cell Biol.* **1984**, *98*, 427–435. [CrossRef]

20. Jones, P.A.; Taylor, S.M. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* **1980**, *20*, 85–93. [CrossRef]

21. Konieczny, S.F.; Emerson, C.P., Jr. 5-Azacytidine induction of stable mesodermal stem cell lineages from 10T1/2 cells: Evidence for regulatory genes controlling determination. *Cell* **1984**, *38*, 791–800. [CrossRef]

22. Taylor, S.M.; Jones, P.A. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. *Cell* **1979**, *17*, 771–779. [CrossRef]

23. Davis, R.L.; Weintraub, H.; Lassar, A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* **1987**, *51*, 987–1000. [CrossRef]

24. Choi, J.; Costa, M.L.; Mermelstein, C.S.; Chagas, C.; Holtzer, S.; Holtzer, H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 7988–7992. [CrossRef]

25. Weintraub, H.; Tapscott, S.J.; Davis, R.L.; Thayer, M.J.; Adam, M.A.; Lassar, A.B.; Miller, A.D. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 5434–5438. [CrossRef]

26. Gascon, S.; Masserodtti, G.; Russo, G.L.; Gotz, M. Direct Neuronal Reprogramming: Achievements, Hurdles, and New Roads to Success. *Cell Stem Cell* **2017**, *21*, 18–34. [CrossRef]

27. Tanabe, K.; Haag, D.; Wernig, M. Direct somatic lineage conversion. *Philos. Trans. R. Soc. B Biol. Sci.* **2015**, *370*, 20143068. [CrossRef]

28. Chen, Y.; Yang, Z.; Zhao, Z.A.; Shen, Z. Direct reprogramming of fibroblasts into cardiomyocytes. *Stem Cell Res. Ther.* **2017**, *8*, 118. [CrossRef]

29. Srivastava, D.; Yu, P. Recent advances in direct cardiac reprogramming. *Curr. Opin. Genet. Dev.* **2015**, *25*, 77–81. [CrossRef]

30. Graf, T. Historical origins of transdifferentiation and reprogramming. *Cell Stem Cell* **2011**, *9*, 504–516. [CrossRef]

31. Graf, T.; Enver, T. Forcing cells to change lineages. *Nature* **2009**, *462*, 587–594. [CrossRef] [PubMed]

32. Wild, S.L.; Tosh, D. Molecular mechanisms of transcription factor mediated cell reprogramming: Conversion of liver to pancreas. *Biochem. Soc. Trans.* **2021**, *49*, 579–590. [CrossRef] [PubMed]

33. Zaret, K.S. Pioneer Transcription Factors Initiating Gene Network Changes. *Annu. Rev. Genet.* **2020**, *54*, 367–385. [CrossRef] [PubMed]

34. Chan, S.S.; Kyba, M. What is a Master Regulator? *Stem Cell Res. Ther.* **2013**, *3*, 2. [CrossRef]

35. Bartorelli, V.; Puri, P.L. Shaping Gene Expression by Landscaping Chromatin Architecture: Lessons from a Master. *Mol. Cell* **2018**, *71*, 373–388. [CrossRef]

36. Murre, C. Helix-loop-helix proteins and the advent of cellular diversity: 30 years of discovery. *Genes Dev.* **2019**, *33*, 6–25. [CrossRef]

37. Ishibashi, J.; Perry, R.L.; Asakura, A.; Rudnicki, M.A. MyoD induces myogenic differentiation through cooperation of its NH2- and COOH-terminal regions. *J. Cell Biol.* **2005**, *171*, 471–482. [CrossRef]

38. Ma, P.C.; Rould, M.A.; Weintraub, H.; Pabo, C.O. Crystal structure of MyoD bHLH-domain-DNA complex: Perspectives on DNA recognition and implications for transcriptional activation. *Cell* **1994**, *77*, 451–459. [CrossRef]

39. Lassar, A.B.; Davis, R.L.; Wright, W.E.; Kadesch, T.; Murre, C.; Voronova, A.; Baltimore, D.; Weintraub, H. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. *Cell* **1991**, *66*, 305–315. [CrossRef]

40. Blackwell, T.K.; Weintraub, H. Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. *Science* **1990**, *250*, 1104–1110. [CrossRef]
41. Fong, A.P.; Yao, Z.; Zhong, J.W.; Cao, Y.; Ruzzo, W.L.; Gentleman, R.C.; Tappcott, S.J. Genetic and epigenetic determinants of neurogenesis and myogenesis. Dev. Cell 2012, 22, 721–735. [CrossRef] [PubMed]
42. Fong, A.P.; Yao, Z.; Zhong, J.W.; Johnson, N.M.; Farr, G.H.; 3rd, Maves, L.; Tappcott, S.J. Conversion of MyoD to a neurogenic factor: Binding site specificity determines lineage. Cell Rep. 2015, 10, 1937–1946. [CrossRef] [PubMed]
43. Soleimani, V.D.; Nguyen, D.; Ramachandran, P.; Palidwor, G.A.; Porter, C.J.; Yin, H.; Perkins, T.J.; Rudnicki, M.A. cis-regulatory determinants of MyoD function. Nucleic Acids Res. 2018, 46, 7221–7235. [CrossRef] [PubMed]
44. Molkentin, J.D.; Black, B.L.; Martin, J.F.; Olson, E.N. Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell 1995, 83, 1125–1136. [CrossRef]
45. Taylor, M.V.; Hughes, S.M. Mef2 and the skeletal muscle differentiation program. Semin. Cell Dev. Biol. 2017, 72, 33–44. [CrossRef]
46. Biesiada, E.; Hamamori, Y.; Kedes, L.; Sartorelli, V. Myogenic basic helix-loop-helix proteins and Sp1 interact as components of a multiprotein transcriptional complex required for activity of the human cardiac alpha-actin promoter. Mol. Cell. Biol. 1999, 19, 2577–2584. [CrossRef]
47. Guo, C.S.; Degnin, C.; Fiddler, T.A.; Stauffer, D.; Thayer, M.J. Regulation of MyoD activity and muscle cell differentiation by MDM2, pRB, and Sp1. J. Biol. Chem. 2003, 278, 22665–22672. [CrossRef]
48. Berkes, C.A.; Bergstrom, D.A.; Penn, B.H.; Seaver, K.J.; Knoepfler, P.S.; Tappcott, S.J. Pbx marks genes for activation by MyoD indicating a role for a homeodomain protein in establishing myogenic potential. Mol. Cell. 2004, 14, 465–477. [CrossRef]
49. Liu, Y.; Chu, A.; Chakroun, I.; Islam, U.; Blais, A. Cooperation between myogenic regulatory factors and SIX family transcription factors is important for myoblast differentiation. Nucleic Acids Res. 2010, 38, 6857–6871. [CrossRef]
50. Blum, R.; Vethanatham, V.; Bowman, C.; Rudnicki, M.; Dynlacht, B.D. Genome-wide identification of enhancers in skeletal muscle: The role of MyoD1. Genes Dev. 2012, 26, 2763–2779. [CrossRef]
51. Cao, Y.; Yao, Z.; Sarkar, D.; Lawrence, M.; Sanchez, G.J.; Parker, M.H.; MacQuarrie, K.L.; Davison, J.; Morgan, M.T.; Ruzzo, W.L.; et al. Genome-wide MyoD binding in skeletal muscle cells: A potential for broad cellular reprogramming. Dev. Cell 2010, 18, 662–674. [CrossRef] [PubMed]
52. Boyarchuk, E.; Robin, P.; Fritsch, L.; Joliot, V.; Ait-Si-Ali, S. Identification of MyoD Interactome Using Tandem Affinity Purification Coupled to Mass Spectrometry. J. Vis. Exp. 2016, 111, e53924. [CrossRef]
53. Singh, K.; Cassano, M.; Planet, E.; Sebastian, S.; Jang, S.M.; Sohi, G.; Faralli, H.; Choi, J.; Youn, H.D.; Dilworth, F.J.; et al. A KAP1 phosphorylation switch controls MyoD function during skeletal muscle differentiation. Genes Dev. 2015, 29, 513–525. [CrossRef] [PubMed]
54. Deato, M.D.; Marr, M.T.; Sottero, T.; Inouye, C.; Hu, P.; Tjian, R. MyoD targets TAF3/TRF3 to activate myogenin transcription. Mol. Cell 2008, 32, 96–105. [CrossRef] [PubMed]
55. Heller, H.; Bengal, E. TFIID (TBP) stabilizes the binding of MyoD to its DNA site at the promoter and MyoD facilitates the association of TFIIB with the preinitiation complex. Nucleic Acids Res. 1998, 26, 2112–2119. [CrossRef]
56. Giacinti, C.; Bagella, L.; Puri, P.L.; Giordano, A.; Simone, C. MyoD recruits the cdk9/cyclin T2 complex on myogenic-genes regulatory regions. J. Cell. Physiol. 2006, 206, 807–813. [CrossRef]
57. Simone, C.; Stiegler, P.; Bagella, L.; Pucci, B.; Bellan, C.; De Falco, G.; De Luca, A.; Guanti, G.; Puri, P.L.; Giordano, A. Activation of MyoD-dependent transcription by cdk9/cyclin T2. Oncogene 2002, 21, 4137–4148. [CrossRef]
58. Benezra, R.; Davis, R.L.; Lockshon, D.; Turner, D.L.; Weintraub, H. The protein Id: A negative regulator of helix-loop-helix DNA binding proteins. Cell 1990, 61, 49–59. [CrossRef]
59. Lu, J.; Webb, R.; Richardson, J.A.; Olson, E.N. MyoR: A muscle-restricted basic helix-loop-helix transcription factor that antagonizes the actions of MyoD. Proc. Natl. Acad. Sci. USA 1999, 96, 552–557. [CrossRef]
60. MacQuarrie, K.L.; Yao, Z.; Fong, A.P.; Tappcott, S.J. Genome-wide binding of the basic helix-loop-helix myogenic inhibitor musclein has substantial overlap with MyoD: Implications for buffering activity. Skelet. Muscle 2013, 3, 26. [CrossRef]
61. Li, S.; Chen, K.; Zhang, Y.; Barnes, S.D.; Jaichander, P.; Zheng, Y.; Hassan, M.; Malladi, V.S.; Skapek, S.X.; Xu, L.; et al. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. Genes Dev. 2019, 33, 626–640. [CrossRef] [PubMed]
62. Spicer, D.B.; Rhee, J.; Cheung, W.L.; Lassar, A.B. Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 1992, 267, 1476–1480. [CrossRef] [PubMed]
63. Lemercier, C.; To, R.Q.; Carrasco, R.A.; Konieczny, S.F. The basic helix-loop-helix transcription factor Mist1 functions as a transcriptional repressor of myoD. EMBO J. 1998, 17, 1412–1422. [CrossRef] [PubMed]
64. Soleimani, V.D.; Yin, H.; Jahanian-Asl, A.; Ming, H.; Kockx, C.E.; van Ijken, W.F.; Grosveld, F.; Rudnicki, M.A. Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. Mol. Cell. 2012, 47, 457–468. [CrossRef]
65. Siles, L.; Sanchez-Tillo, E.; Lim, J.W.; Darling, D.S.; Kroll, K.L.; Postigo, A. ZEB1 imposes a temporary stage-dependent inhibition of muscle gene expression and differentiation via CtBP-mediated transcriptional repression. Mol. Cell. Biol. 2013, 33, 1368–1382. [CrossRef]
66. Segales, J.; Islam, A.B.; Kumar, R.; Liu, Q.C.; Sousa-Victor, P.; Dilworth, F.J.; Ballestar, E.; Perdiguerro, E.; Munoz-Canoves, P. Chromatin-wide and transcriptionite profiling integration uncovers p38alpha MAPK as a global regulator of skeletal muscle differentiation. Skelet. Muscle 2016, 6, 9. [CrossRef]
Cells 2022, 11, 3435

67. Simone, C.; Forcales, S.V.; Hill, D.A.; Imbalzano, A.N.; Latella, L.; Puri, P.L. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat. Genet. 2004, 36, 738–743. [CrossRef]

68. Zetter, A.; Grederinger, E.; Bengal, E. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mel2c transcription factor. J. Biol. Chem. 1999, 274, 5193–5200. [CrossRef]

69. Buas, M.F.; Kabak, S.; Kadesch, T. The Notch effector Hey1 associates with myogenic target genes to repress myogenesis. J. Biol. Chem. 2010, 285, 1249–1258. [CrossRef]

70. Wei, Q.; Paterson, B.M. Regulation of MyoD function in the dividing myoblast. FEBS Lett. 2001, 490, 171–178. [CrossRef]

71. Dall’Agnese, A.; Caputo, L.; Nicoletti, C.; di Iulio, J.; Schmitt, A.; Gatto, S.; Diao, Y.; Ye, Z.; Forcato, M.; Perera, R.; et al. Transcription Factor-Directed Re-wiring of Chromatin Architecture for Somatic Cell Nuclear Reprogramming toward trans-Differentiation. Mol. Cell 2019, 76, 453–472. [CrossRef] [PubMed]

72. Bergstrom, D.A.; Penn, B.H.; Strand, A.; Perry, R.L.; Rudnicki, M.A.; Tapscott, S.J. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Mol. Cell 2002, 9, 587–600. [CrossRef]

73. Thayer, M.J.; Tapscott, S.J.; Davis, R.L.; Wright, W.E.; Lassar, A.B.; Weintraub, H. Positive autoregulation of the myogenic determination gene MyoD1. Cell 1989, 58, 241–248. [CrossRef]

74. Blais, A.; Tsikitis, M.; Acosta-Alvear, D.; Sharan, R.; Kluger, Y.; Dynlacht, B.D. An initial blueprint for myogenic differentiation. Genes Dev. 2005, 19, 553–569. [CrossRef]

75. Penn, B.H.; Bergstrom, D.A.; Dilworth, F.J.; Bengal, E.; Tapscott, S.J. A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation. Genes Dev. 2004, 18, 2348–2353. [CrossRef]

76. Manandhar, D.; Song, L.; Kabadi, A.; Kwon, J.B.; Edsall, L.E.; Ehrlich, M.; Tsumagari, K.; Gersbach, C.A.; Crawford, G.E.; Gordan, R. Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies. Nucleic Acids Res. 2017, 45, 11684–11699. [CrossRef]

77. Rosenberg, M.I.; Forcales, S.V.; Hill, D.A.; Imbalzano, A.N.; Latella, L.; Puri, P.L. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat. Genet. 2004, 36, 738–743. [CrossRef]

78. Zammit, P.S. Function of the myogenic regulatory factors Myf5, MyoD, Myogenin and MRF4 in skeletal muscle, satellite cells and regenerative myogenesis. Mol. Cell. Biol. 2011, 31, 738–743. [CrossRef] [PubMed]

79. Wright, W.E.; Sassoon, D.A.; Lin, V.K. Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Proc. Natl. Acad. Sci. USA 2003, 100, 1735–1739. [CrossRef] [PubMed]

80. Braun, T.; Buschhausen-Denker, G.; Bober, E.; Tannich, E.; Arnold, H.H. A novel human muscle factor related to but distinct from Fascin1. J. Biol. Chem. 2003, 278, 50147–50156. [CrossRef]

81. Rhodes, S.J.; Konieczny, S.F. Identification of MRF4: A new member of the muscle regulatory factor gene family. Genes Dev. 1989, 3, 2050–2061. [CrossRef] [PubMed]

82. Asfour, H.A.; Allouh, M.Z.; Said, R.S. Myogenic regulatory factors: The orchestrators of myogenesis after 30 years of discovery. Exp. Biol. Med. 2018, 243, 118–128. [CrossRef] [PubMed]

83. Hernandez-Hernandez, J.M.; Garcia-Gonzalez, E.G.; Bruhn, C.E.; Rudnicki, M.A. The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration. Semin. Cell Dev. Biol. 2017, 72, 10–18. [CrossRef] [PubMed]

84. Zammit, P.S. Function of the myogenic regulatory factors Myf5, MyoD, Myogenin and MRF4 in skeletal muscle, satellite cells and regenerative myogenesis. Semin. Cell Dev. Biol. 2017, 72, 19–32. [CrossRef] [PubMed]

85. Bergstrom, D.A.; Tapscott, S.J. Molecular distinction between specification and differentiation in the myogenic basic helix-loop-helix transcription factor family. Mol. Cell. Biol. 2001, 21, 2404–2412. [CrossRef] [PubMed]

86. Gerber, A.N.; Klesert, T.R.; Bergstrom, D.A.; Tapscott, S.J. Two domains of MyoD mediate transcriptional activation of genes in repressive chromatin: A mechanism for lineage determination in myogenesis. Genes Dev. 1997, 11, 436–450. [CrossRef]

87. Cao, Y.; Kumar, R.M.; Penn, B.H.; Berkes, C.A.; Kooperberg, C.; Boyer, L.A.; Young, R.A.; Tapscott, S.J. Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters. EMBO J. 2006, 25, 502–511. [CrossRef]

88. Conerly, M.L.; Yao, Z.; Zhong, J.W.; Groudine, M.; Tapscott, S.J. Distinct Activities of Myf5 and MyoD Indicate Separate Roles in Skeletal Muscle Lineage Specification and Differentiation. Dev. Cell 2015, 36, 375–385. [CrossRef]

89. Bannister, A.J.; Konarzides, T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21, 381–395. [CrossRef]

90. Klemm, S.L.; Shipony, Z.; Greenleaf, W.J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 2019, 20, 207–220. [CrossRef]

91. Rinn, J.L. IncRNAs: Linking RNA to chromatin. Cold Spring Harb. Perspect. Biol. 2014, 6, a018614. [CrossRef] [PubMed]

92. Soufi, A.; Garcia, M.F.; Jaroszewicz, A.; Osman, N.; Pellegrini, M.; Zaret, K.S. Pbx homeodomain proteins direct Myod activity to promote fast-muscle differentiation. Development 2007, 134, 3371–3382. [CrossRef]

93. de la Serna, I.L.; Ohkawa, Y.; Berkes, C.A.; Bergstrom, D.A.; Dacwag, C.S.; Tapscott, S.J.; Imbalzano, A.N. MyoD targets chromatin remodeling complexes to the myogenin locus prior to forming a stable DNA-bound complex. Mol. Cell. Biol. 2005, 25, 3997–4009. [CrossRef] [PubMed]

94. Maves, L.; Waskiewicz, A.J.; Paul, B.; Cao, Y.; Tyler, A.; Moens, C.B.; Tapscott, S.J. Pbx homeodomain proteins direct Myod activity to promote fast-muscle differentiation. Development 2007, 134, 3371–3382. [CrossRef]

95. Dell’Orso, S.; Wang, A.H.; Shih, H.Y.; Saso, K.; Berghella, L.; Gutierrez-Cruz, G.; Ladurner, A.G.; O’Shea, J.J.; Sartorelli, V.; Zare, H. The Histone Variant MacroH2A1.2 Is Necessary for the Activation of Muscle Enhancers and Recruitment of the Transcription Factor Pbx1. Cell Rep. 2016, 14, 1156–1166. [CrossRef]
96. Casey, B.H.; Kollipara, R.K.; Pozo, K.; Johnson, J.E. Intrinsic DNA binding properties demonstrated for lineage-specifying basic
helix-loop-helix transcription factors. *Genome Res.* 2018, 28, 484–496. [CrossRef]

97. de la Serna, I.L.; Carlson, K.A.; Imbalzano, A.N. Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation.
*Nat. Genet.* 2001, 27, 187–190. [CrossRef]

98. Forcades, S.V.; Albini, S.; Giordani, L.; Malecova, B.; Cignolo, L.; Chernov, A.; Coutinho, P.; Saccone, V.; Consalvi, S.; Williams, R.;
et al. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. *EMBO J.* 2012,
31, 301–316. [CrossRef]

99. Harada, A.; Okada, S.; Konno, D.; Odawara, J.; Yoshimi, T.; Yoshimura, S.; Kumamaru, H.; Saiwai, H.; Tsubota, T.; Kurumizaka,
H.; et al. Chd2 interacts with H3.3 to determine myogenic cell fate. *EMBO J.* 2012, 31, 2994–3007. [CrossRef]

100. Puri, P.L.; Avantaggiati, M.L.; Balsano, C.; Sang, N.; Graessmann, A.; Giordano, A.; Levero, M. p300 is required for MyoD-
dependent cell cycle arrest and muscle-specific gene transcription. *EMBO J.* 1997, 16, 369–383. [CrossRef]

101. Yuan, W.; Condorelli, G.; Caruso, M.; Felsani, A.; Giordano, A. Human p300 protein is a coactivator for the transcription factor
MyoD. *J. Biol. Chem.* 1996, 271, 9009–9013. [CrossRef] [PubMed]

102. Dilworth, F.J.; Seaver, K.J.; Fishburn, A.L.; Htet, S.L.; Tapscott, S.J. In vitro transcription system delineates the distinct roles of the
coactivators pCAF and p300 during MyoD/E47-dependent transactivation. *Proc. Natl. Acad. Sci. USA* 2004, 101, 11593–11598.
[CrossRef] [PubMed]

103. Puri, P.L.; Sartorelli, V.; Yang, X.J.; Hamamori, Y.; Ogryzko, V.V.; Howard, B.H.; Kedes, L.; Wang, J.Y.; Graessmann, A.; Nakatani,
Y.; et al. Differential roles of p300 and P300/CBFα in muscle differentiation. *Mol. Cell* 1997, 1, 35–45. [CrossRef]

104. Tao, Y.; Nepple, R.L.; Huang, Z.P.; Chen, J.; Tang, R.H.; Cao, R.; Zhang, Y.; Jin, S.W.; Wang, D.Z. The histone methyltransferase
Set9/7 promotes myoblast differentiation and myofibril assembly. *J. Cell. Biol.* 2011, 194, 551–565. [CrossRef]

105. Dacwag, C.S.; Ohkawa, Y.; Pal, S.; Sif, S.; Imbalzano, A.N. The protein arginine methyltransferase Prmt5 is required for myogenesis
because it facilitates ATP-dependent chromatin remodeling. *Mol. Cell. Biol.* 2007, 27, 384–394. [CrossRef]

106. Choi, J.; Jang, H.; Kim, H.; Kim, S.T.; Cho, E.J.; Youn, H.D. Histone demethylase LSD1 is required to induce skeletal muscle
differentiation by regulating intracellular factors. *Biochem. Biophys. Res. Commun.* 2010, 401, 327–332. [CrossRef]

107. Chakroun, I.; Yang, D.; Girgis, J.; Gunasekharan, A.; Phenix, H.; Kaern, M.; Blais, A. Genome-wide association between Six4,
31, 3042, 32464–32475. [CrossRef] [PubMed]

108. Caretti, G.; Schiltz, R.L.; Dilworth, F.J.; Di Padova, M.; Zhao, P.; Ogryzko, V.; Fuller-Pace, F.V.; Hoffman, E.P.; Tapscott,
S.J.; Sartorelli, V. The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle
differentiation. *Proc. Natl. Acad. Sci. USA* 2020, 117, 32464–32475. [CrossRef] [PubMed]

109. Harada, A.; Okada, S.; Konno, D.; Odawara, J.; Yoshimi, T.; Yoshimura, S.; Kumamaru, H.; Saiwai, H.; Tsubota, T.; Kurumizaka,
H.; et al. Chd2 interacts with H3.3 to determine myogenic cell fate. *EMBO J.* 2012, 31, 2994–3007. [CrossRef]

110. Yu, X.; Zhang, Y.; Li, T.; Malecova, B.; Cignolo, L.; Chernov, A.; Coutinho, P.; Saccone, V.; Consalvi, S.; Williams, R.;
et al. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. *EMBO J.* 2012,
31, 301–316. [CrossRef]

111. Ling, B.M.; Bharathy, N.; Chung, T.K.; Kok, W.K.; Li, S.; Tan, Y.H.; Rao, V.K.; Gopinadhan, S.; Sartorelli, V.; Walsh, M.J.;
et al. Lysine methyltransferase G9a methylates the transcription factor MyoD and regulates skeletal muscle differentiation. *Proc. Natl.
Acad. Sci. USA* 2012, 109, 841–846. [CrossRef]

112. Andresini, O.; Rossi, M.N.; Matteini, F.; Petrai, S.; Santini, T.; Maione, R. The long non-coding RNA Kcnq1ot1 controls maternal
p57 expression in muscle cells by promoting H3K27me3 accumulation to an intragenic MyoD-binding region. *Epigenetics
Chromatin* 2019, 12, 8. [CrossRef] [PubMed]

113. Battistelli, C.; Busanello, A.; Maione, R. Functional interplay between MyoD and CTCF in regulating long-range chromatin
interactions during differentiation. *J. Cell Sci.* 2014, 127, 3757–3767. [CrossRef] [PubMed]

114. Harada, A.; Mallappa, C.; Okada, S.; Butler, J.T.; Baker, S.P.; Lawrence, J.B.; Ohkawa, Y.; Imbalzano, A.N. Spatial reorganization
of myogenic regulatory sequences controls gene expression. *Nucleic Acids Res.* 2015, 43, 2008–2021. [CrossRef]

115. Wang, R.; Chen, F.; Chen, Q.; Wan, X.; Shi, M.; Chen, A.K.; Ma, Z.; Li, G.; Wang, M.; Ying, Y.; et al. MyoD is a 3D genome structure
organizer for muscle cell identity. *Nat. Commun.* 2022, 13, 205. [CrossRef] [PubMed]

116. Clapier, C.R.; Ivaska, J.; Cairns, B.R.; Peterson, C.L. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling
complexes. *Nat. Rev. Mol. Cell Biol.* 2017, 18, 407–422. [CrossRef]

117. Polelskaya, A.; Duquet, A.; Naguibneva, I.; Weise, C.; Vervisch, A.; Bencs, E.; Hucok, F.; Robin, P.; Harel-Bellan, A. CREB-binding
protein/p300 activates MyoD by acetylation. *J. Biol. Chem.* 2000, 275, 34359–34364. [CrossRef]

118. Heinz, S.; Romanoski, C.E.; Benner, C.; Glass, C.K. The selection and function of cell type-specific enhancers. *Nat. Rev. Mol. Cell
Biol.* 2015, 16, 144–154. [CrossRef]

119. Mal, A.K. Histone methyltransferase Suv39h1 represses MyoD-stimulated myogenic differentiation. *EMBO J.* 2006, 25, 3323–3334.
[CrossRef]

120. Ling, B.M.; Bharathy, N.; Chung, T.K.; Kok, W.K.; Li, S.; Tan, Y.H.; Rao, V.K.; Gopinadhan, S.; Sartorelli, V.; Walsh, M.J.;
et al. Lysine methyltransferase G9a methylates the transcription factor MyoD and regulates skeletal muscle differentiation. *Proc. Natl.
Acad. Sci. USA* 2012, 109, 841–846. [CrossRef]

121. Caretti, G.; Di Padova, M.; Micales, B.; Lyons, G.E.; Sartorelli, V. The Polycomb Ezh2 methyltransferase regulates muscle gene
expression and skeletal muscle differentiation. *Genes Dev.* 2004, 18, 2627–2638. [CrossRef] [PubMed]
Cells 2022, 11, 3435

122. Juan, A.H.; Kumar, R.M.; Marx, J.G.; Young, R.A.; Sartorelli, V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol. Cell 2009, 36, 61–74. [CrossRef] [PubMed]

123. Schwartzman, J.M.; Reuter, V.P.; Koche, R.P.; Thompson, C.B. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation. Proc. Natl. Acad. Sci. USA 2011, 108, 12851–12856. [CrossRef] [PubMed]

124. Ballarino, M.; Morlando, M.; Fatica, A.; Bozzoni, I. Non-coding RNAs in muscle differentiation and musculoskeletal disease. J. Clin. Invest. 2016, 126, 2021–2030. [CrossRef]

125. Neguembor, M.V.; Jothi, M.; Gabellini, D. Long noncoding RNAs, emerging players in muscle differentiation and disease. Skelet. Muscle 2014, 4, 8. [CrossRef] [PubMed]

126. Wang, S.; Jin, J.; Xu, Z.; Zuo, B. Functions and Regulatory Mechanisms of IncRNAs in Skeletal Myogenesis, Muscle Disease and Meat Production. Cells 2019, 8, 1107. [CrossRef] [PubMed]

127. Wongtrakoongate, P.; Riddick, G.; Fucharoen, S.; Felsenfeld, G. Association of the Long Non-coding RNA Steroid Receptor RNA Activator (SRA) with TrxG and PRC2 Complexes. PLoS Genet. 2015, 11, e1005615. [CrossRef] [PubMed]

128. Yao, H.; Brick, K.; Evrad, Y.; Xiao, T.; Camerini-Otero, R.D.; Felsenfeld, G. Mediation of CTCF transcriptional insulation by DEAD-box RNA-binding protein p68 and steroid receptor RNA activator SRA. Genes Dev. 2010, 24, 2543–2555. [CrossRef]

129. Gong, C.; Li, Z.; Ramanujan, K.; Clay, I.; Zhang, Y.; Lemire-Brachat, S.; Glass, D.J. A long non-coding RNA, LncMyoD, regulates skeletal muscle differentiation by blocking IMP2-mediated mRNA translation. Dev. Cell 2015, 34, 181–191. [CrossRef]

130. Mousavi, K.; Zare, H.; Dell’orso, S.; Grontved, L.; Gutierrez-Cruz, G.; Derfoul, A.; Hager, G.L.; Sartorelli, V. eRNAs promote transcription by establishing chromatin accessibility at defined genomic loci. Mol. Cell 2013, 51, 606–617. [CrossRef] [PubMed]

131. Mueller, A.C.; Cichewicz, M.A.; Dey, B.K.; Layer, R.; Reon, B.J.; Gagan, J.R.; Dutta, A. MUNC, an Enhancer RNA Upstream from the MyoD Gene. Mol. Cell. Biol. 2018, 38, e00655-17. [CrossRef]

132. Mousavi, K.; Zare, H.; Dell’orso, S.; Grontved, L.; Gutierrez-Cruz, G.; Derfoul, A.; Hager, G.L.; Sartorelli, V. eRNAs promote transcription by establishing chromatin accessibility at defined genomic loci. Mol. Cell 2013, 51, 606–617. [CrossRef] [PubMed]

133. Muller, A.C.; Cichewicz, M.A.; Dey, B.K.; Layer, R.; Reon, B.J.; Gagan, J.R.; Dutta, A. MUNC, an Enhancer RNA Upstream from the MyoD Gene. Mol. Cell. Biol. 2018, 38, e00655-17. [CrossRef]

134. Van Bortle, K.; Corces, V.G. Nuclear organization and genome function. Curr. Opin. Genet. Dev. 2012, 22, 59–61. [CrossRef] [PubMed]

135. Felsenfeld, G.; Dekker, J. Genome architecture and expression. Curr. Opin. Genet. Dev. 2012, 22, 59–61. [CrossRef] [PubMed]

136. Di Giammartino, D.C.; Polyzos, A.; Apostolou, E. Transcription factors: Building hubs in the 3D space. Cell Cycle 2012, 11, 8266–8275. [CrossRef]

137. Misteli, T. The Self-Organizing Genome: Principles of Genome Architecture and Function. Mol. Cell 2012, 35, 498–513. [CrossRef] [PubMed]

138. Hnisz, D.; Day, D.S.; Young, R.A. Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control. Curr. Opin. Genet. Dev. 2012, 22, 163–187. [CrossRef] [PubMed]

139. Di Giammartino, D.C.; Polyzos, A.; Apostolou, E. Transcription factors: Building hubs in the 3D space. Cell Cycle 2012, 11, 2395–2410. [CrossRef] [PubMed]

140. Cacchiarelli, D.; Qiu, X.; Srivatsan, S.; Manfredi, A.; Ziller, M.; Overby, E.; Grimaldi, A.; Grimsby, J.; Pokharel, P.; Livak, K.J.; et al. Aligning Single-Cell Developmental and Reprogramming Trajectories Identifies Molecular Determinants of Myogenic Reprogramming Outcome. Cell Syst. 2018, 7, 258–268. [CrossRef]
150. Figliola, R.; Maione, R. MyoD induces the expression of p57Kip2 in cells lacking p21Cip1/Waf1: Overlapping and distinct functions of the two cdk inhibitors. *J. Cell. Physiol.* **2004**, *200*, 468–475. [CrossRef]

151. Andresini, O.; Ciotti, A.; Rossi, M.N.; Battistelli, C.; Carbone, M.; Maione, R. A cross-talk between DNA methylation and H3 lysine 9 dimethylation at the KvDMR1 region controls the induction of Cdkn1c in muscle cells. *Epigenetics* **2016**, *11*, 791–803. [CrossRef] [PubMed]

152. Figliola, R.; Busanello, A.; Vaccarello, G.; Maione, R. Regulation of p57(KIP2) during muscle differentiation: Role of Egr1, Sp1 and DNA hypomethylation. *J. Mol. Biol.* **2008**, *380*, 265–277. [CrossRef] [PubMed]

153. Matteini, F.; Andresini, O.; Petrai, S.; Battistelli, C.; Rossi, M.N.; Maione, R. Poly(ADP-ribose) Polymerase 1 (PARP1) restrains MyoD-dependent gene expression during muscle differentiation. *Sci. Rep.* **2020**, *10*, 15086. [CrossRef] [PubMed]

154. Bar-Nur, O.; Gerli, M.F.M.; Di Stefano, B.; Almada, A.E.; Galvin, A.; Coffey, A.; Huebner, A.J.; Feige, P.; Verheul, C.; Cheung, P.; et al. Direct Reprogramming of Mouse Fibroblasts into Functional Skeletal Muscle Progenitors. *Stem Cell Rep.* **2018**, *10*, 1505–1521. [CrossRef]

155. Kim, I.; Ghosh, A.; Bundschuh, N.; Hinte, L.; Petrosyan, E.; von Meyenn, F.; Bar-Nur, O. Integrative molecular roadmap for direct conversion of fibroblasts into myocytes and myogenic progenitor cells. *Sci. Adv.* **2022**, *8*, eabj4928. [CrossRef]

156. Yagi, M.; Ji, F.; Charlton, J.; Cristea, S.; Messemper, K.; Horwitz, N.; Di Stefano, B.; Tsopoulidis, N.; Hoetker, M.S.; Huebner, A.J.; et al. Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells. *Genes Dev.* **2021**, *35*, 1209–1228. [CrossRef]

157. Jalal, S.; Dastidar, S.; Tedesco, F.S. Advanced models of human skeletal muscle differentiation, development and disease: Three-dimensional cultures, organoids and beyond. *Curr. Opin. Cell Biol.* **2021**, *73*, 92–104. [CrossRef]